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Background: We report the initial results from a phase I clinical trial for ALS. We transplanted GMP-grade, fetal
human neural stem cells from natural in utero death (hNSCs) into the anterior horns of the spinal cord to test for
the safety of both cells and neurosurgical procedures in these patients. The trial was approved by the Istituto
Superiore di Sanità and the competent Ethics Committees and was monitored by an external Safety Board.
Methods: Six non-ambulatory patients were treated. Three of them received 3 unilateral hNSCs microinjections into
the lumbar cord tract, while the remaining ones received bilateral (n = 3 + 3) microinjections. None manifested severe
adverse events related to the treatment, even though nearly 5 times more cells were injected in the patients receiving
bilateral implants and a much milder immune-suppression regimen was used as compared to previous trials.
Results: No increase of disease progression due to the treatment was observed for up to18 months after surgery.
Rather, two patients showed a transitory improvement of the subscore ambulation on the ALS-FRS-R scale (from 1 to 2).
A third patient showed improvement of the MRC score for tibialis anterior, which persisted for as long as 7 months.
The latter and two additional patients refused PEG and invasive ventilation and died 8 months after surgery due to the
progression of respiratory failure. The autopsies confirmed that this was related to the evolution of the disease.
Conclusions: We describe a safe cell therapy approach that will allow for the treatment of larger pools of patients
for later-phase ALS clinical trials, while warranting good reproducibility. These can now be carried out under more
standardized conditions, based on a more homogenous repertoire of clinical grade hNSCs. The use of brain tissue
from natural miscarriages eliminates the ethical concerns that may arise from the use of fetal material.
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Amyotrophic Lateral Sclerosis (ALS) is a devastating, in-
curable neurodegenerative disease that targets motor
neurons (MNs) in the primary motor cortex, brainstem,
and spinal cord. Cell therapy is emerging as a potential
therapeutic option in ALS, although numerous scientific,
technical, ethical and regulatory issues remain to be
overcome. One critical issue pertains to the type of stem
cells to be used in cell therapy for ALS. Donor cells
must not only survive in the human central nervous
system (CNS), but ought to be capable of improving the
tissue pathophysiological condition, possibly by modulat-
ing local inflammatory and immune reactions and by
antagonizing toxic phenomena [1,2]. Notwithstanding,
the first critical requirement that stem cells must meet
in clinical applications concerns their safety. At the same
time, a pressing need exists for them to be easily isolated
and reproducibly and stably expanded ex vivo [3]. Thus,
both hematopoietic and mesenchymal stem cells (MSCs)
have now been transplanted into the spinal cord of ALS
patients, in the absence of long-term negative effects
[4-6]. Others and we have previously documented the
integration capacity and prospective therapeutic efficacy
of human neural stem cells (hNSC) in preclinical rodent
models of neurological diseases [7-10]. Of interest, we
showed that, when implanted either intravenously or
intrathecally, NSC ameliorate the pathophysiological and
neurological traits in an experimental model of auto-
immune encephalomyelitis, both in rodents [11] and
non-human primates [12]. A key conclusion from these
studies was that implanted NSCs would integrate and
survive predominantly as astroglial cells. These would
likely elicited their effects through the release of growth
factors and immunomodulatory molecules [12].
The injection of candidate therapeutic cells in the
proximity of the degeneration site(s) may better suit the
key requirements in the neural transplantation context.
In ALS, engraftment of donor cells close to the dying
MNs might favour the diffusion of trophic and immuno-
modulatory factors to both the MNs themselves and the
surrounding glial cells, thereby enhancing the likelihood
of accomplishing therapeutic effects. Accordingly, a
meta-analysis of 11 independent studies demonstrated
that, when implanted close to the dying MNs, NSCs
may slow both the onset and the progression of clinical
signs and can prolong overall survival in ALS mice [13].
Furthermore, it has recently been shown that transplant-
ation of human neural progenitor cells into the ventral
cervical spinal cords of SOD1G93A rats can slow the
death of phrenic motor neuron and increase activity in
spared phrenic MNs [14].
A technique for the focal delivery of donor cells in the
proximity of ventral MNs has recently been established
using a stabilized, stereotaxic frame [15]. This system,previously standardized in animal models [16,17], has
now been employed in the first FDA-approved cell-
therapy trial for ALS, implanting human neural pro-
genitor cells [18,19].
Here we expand on these studies and report the pre-
liminary results from a first group of six ALS patients in
an ongoing Phase I trial, in which bona fide, multipotent
hNSCs were isolated and reproducibly expanded from
human fetal tissue. These cells were obtained from
spontaneous miscarriages [8] and implanted using a
stereotaxic/surgical apparatus and injection procedures
similar to those used by Riley and colleagues [17].
Methods
The study was performed as a prospective, open pilot
study. The trial was approved and monitored by the
competent Italian authorities, i.e. the Istituto Superiore
di Sanità (ISS), Agenzia Italiana del Farmaco (AIFA,
member of the European Medicine Agency) and by
the Ethics Committees of the Umbria Region, of the
“Maggiore della Carità” and of the “San Antonio” Hospi-
tals. It goes by the European Clinical Trials Database
(EudraCT) identification number 2009-014484-39. All
patients provided written, informed consent. All the re-
corded data for the recruited patients concerning the
whole follow-up period were registered in the “Database
For Clinical Studies With Gene And Somatic Therapy”
of the ISS. The same data were also communicated to an
independent Safety Monitoring Board of multidisciplin-
ary experts, whom controlled strict compliance with the
protocol and monitored possible adverse events.
Patients
Patients were deemed eligible when they had definite or
probable sporadic ALS, according to the El Escorial Re-
vised Criteria [20]. Given the high iatrogenic risk, pa-
tients in this initial study were selected whom suffered
from severe functional impairment in their lower limbs.
The detailed list of inclusion and exclusion criteria is re-
ported in Table 1. All patients received ordinary medical
treatment, including riluzole.
We expected a large impact on the mass media and
inferred that this kind of trial would raise significant ex-
pectations in a large population of patients. Hence, in
order to deal with the likely rather large number of pos-
sible applications, a toll-free phone number and a web-
based portal were set up. Thorough this, patients could
apply for admission to the trial by filling out a form and
by sending a standardized set of clinical information for
initial screening. The neurologists of the staff reviewed
these submissions and eligible patients were summoned
for a visit at the recruitment centres, until the maximum
number of patients allotted by the recruitment criteria
was reached.
Table 1 Inclusion and exclusion criteria
Inclusion Criteria Exclusion Criteria
Age 20 to 75 years Psychiatric disease or other
neurological disease different
from ALS
Non ambulatory (walking subscore
0–1 of the ALS-FRS-R scale)
Evidence of any concurrent
illness
Evidence of progression disease in





Absence of sleep apneas or
hypopneas with blood oxygen
saturation lower than 90%,*
Mental deterioration or
cognitive sphere disturbance
FVC higher than 60% Non-invasive ventilation (NIV) >6
hours daily Patients unable to
understand informed consent
form and study aims
Supposed good adherence
to study protocol
Women who were pregnant or
childbearing potential for the
duration of the study.
Good acceptance and understanding
of the informed consent
*nocturnal respiratory monitoring by polysomnography.
**We excluded patients who received these treatments in the 6 months prior
to the transplant.
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whose experts verified the appropriate adherence to
the protocol and authorized the treatment. At this point
the patients were informed of their recruitment into the
study.
The informed consent was structured as an interview,
which openly and clearly stated the experimental and
preliminary nature of our clinical study and the risks as-
sociated with the procedure. The neurologist discussed
each question with the patients and their relatives. This
procedure was in agreement with the recommendations
of the International Society for Stem Cell Research [21].
Subjects were made aware that their participation in this
study was entirely voluntary and that participation or
non-participation would not interfere with their ongoing
clinical care. Before signing their consent, patients and
close relatives were offered the possibility of meeting
separately with their family physician, a neurosurgeon
and a consultant neurologist, whom were in no manner
involved in our trial, in order to discuss all pending is-
sues. A psychologist closely examined the patients before
and immediately after recruitment. A clinical interview
and the MMPI-2 test were used to ensure that the par-
ticipants fully comprehended that this was a safety trial
and all of the risks associated with the procedure.
Study sites
Patients were enrolled and evaluated at the Tertiary ALS
Centres in Novara and Padova, Italy. All surgical proce-
dures were performed at the “Santa Maria” Hospital inTerni, Italy, in close proximity to the cell factory that
prepared and released the GMP-grade hNSCs upon the
formal authorization granted by AIFA (protocol number
aM 02/2014).
Safety measures
The primary outcome measure was the immediate and
long-term safety profile. Mortality from any cause and
serious adverse effects were the primary occurrences
that were assessed. Patients were closely monitored for
immediate adverse events, including allergic reactions
(tachycardia, fever), respiratory failure, local complications
(intraparenchymal hematoma, local infection at the site of
surgery), systemic complications (systemic infections), par-
alysis or sensory loss below the level of the injection site.
Potential, delayed adverse events included intraspinal
tumor formation, aberrant connections (spinal myoclo-
nus), persistent sensory loss or paralysis not related to the
progression of the disease.
The secondary outcome measures were the difference
in functional outcomes measured by the ALS-FRS-R
scale and forced vital capacity (FVC).
Clinical assessment and follow-up
To estimate the rate of disease progression, patients
were monitored monthly for 1 year and then every three
months, until death. After enrollment, but prior to sur-
gery, each patient was subjected to a three-month obser-
vation period. Clinical progression was assessed using
the ALS-FRS-R, Ashworth Spasticity Scale and the
Medical Research Council (MRC) scale of 34 muscle
groups of the upper and lower limbs and FVC. At each
examination a clinical psychologist also evaluated the
patients. Profile of Mood State (POMS) [22] and
SEIQoL-DW [23] questionnaires were provided to
patients to assess the mood state and the quality of life.
Neuroimaging
Brain and spinal cord (SC) MRIs were obtained using a
1.5-T imaging system (Achieva Intera, Philips). Spinal
cord MRIs were performed pre-operatively and at
21 days and at 3, 6, 9 and 12 months after surgery. Brain
MRIs were performed at the time of entry in the study
and 12 months after surgery. In addition to the full con-
ventional MRI, the spinal cord was imaged by a diffusion
tensor imaging (DTI) pulse sequence in the axial plane,
with 64 directions, in order to identify and quantitatively
characterize the tissue. Using the fiber-tracking algo-
rithm, we calculated the fractional anisotropy (FA) and
apparent diffusion coefficient (ADC) values. We used
FiberTrack Software (Philips, Best, The Netherlands)
and, after a test/re-test for intra-individual variability
evaluation, we measured FA and ADC at the implant
site (T11-T12) and in normal tissue in the upper cervical
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point ROIs. To ensure that the chosen ROIs were effect-
ively inside the spinal cord and part of its architectural
structure we detected and reconstructed a spinal fiber
bundle at each ROI. If not evoked, we discarded that ROIFigure 1 Spinal cord MRI. Upper Panel: Diffusion Tensor Imaging (DTI) o
single point (colored box) ROIs, a correspondent fiber is evoked and reconstru
spinal cord. Lower Panel: DTI post-processing by mean of a MPR algorithm, w
studied at this time of examination and in further MR follow-up scans. Disk anchanging its position (Figure 1 upper panel). To ensure
that at every follow-up the same axial level would be se-
lected, we chose the vascular cleft of the vertebral body
and the midline inside the intervertebral disk between the
somatic endplates as reference sites (Figure 1 lower panel).verlaid with the STIR pulse sequence, in a MPR algorithm. For each of
cted to ensure that the level examined and the ROI adopted is inside the
ith overlaying of the STIR pulse sequence, to select the exact levels to be
d somatic vascular cleft are adopted to select the proper planes.
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program, a high resolution axial T2 weighted image on
the volumetric DTI data. Measurements were carried
out placing two ROIs, right and left, localized in the sup-
posed site of implantation (the grey matter of the anter-
ior horns of the spinal cord). The mean of the two
measures was considered in the analysis for the anterior
part of spinal cord. Another two ROIs were drawn in
correspondence to the posterior spinal bundles, making
for a total of four ROIs for each level.
Blood tests
Blood routine laboratory tests (renal function, liver func-
tion, glucose) and test for Hepatitis B or C, HIV and
TBC were performed at the study entry and 7 days be-
fore surgery. Routine and haematological (full blood
count and CD3+, CD3+/CD8+, CD4+/8+ counts) la-
boratory tests and tacrolimus dosage were performed
weekly during the first post-operative month and then
monthly during the 6 months of the immunosuppression
period.
Urinary bladder evaluation
Bladder ultrasound, measuring the post void residual
volume, was performed at study entry and on the 2nd
and 21st days after surgery and then every three months,
for one year.
Human neural stem cells
The hNSCs used in this clinical trial were produced
according to good manufacturing practice protocols
(GMP), as dictated by the European Medical Agency
(EMA) guidelines. The tissue collection procedure, the
cell factory, the production procedure and the cell valid-
ation criteria received formal approval and certification
by the appropriate regulatory body, namely the Agenzia
Italiana del Farmaco, protocol number aM 101/2010
(updated in 2014 after AIFA inspection to number aM
2/2014). Tissues and cells were procured and handled as
described below [24].
Human fetal tissue
Human fetal brain tissue specimens, all derived from the
forebrain, were routinely collected from fetuses at gesta-
tional ages greater than the 8th post-conceptional week.
They were immediately dissected and used to generate
hNSC lines under sterile conditions. Tissue procurement
was approved by the ethical committee of the Institute
“Casa Sollievo della Sofferenza di San Pio da Pietrelcina”
and was possible exclusively upon the mother giving
informed, written consent. Of note, no tissue from
therapeutic or procured abortion was used in this study
and all of the specimens were collected from fetuses
that underwent natural, spontaneous in utero death,(miscarriage). Also, specimen collection and medical
procedures were in full accord with the Helsinki
declaration (WMA Declaration of Helsinki - Ethical
Principles for Medical Research Involving Human
Subjects). Dissociation of brain tissue, primary cultur-
ing and cell propagation were carried out according to
the procedure described previously by Vescovi and
colleagues [8]. As a whole, the results reported in this
study refer to cells from a maximum of two donors,
whom died at the 15th and 16th gestational week. The
two different cell lines were used randomly to treat
patients.
Primary culturing
Tissue was washed in a PBS solution (Dulbecco’s PBS
1X, PAA plus 50 ng/ml of gentamicin) and mechanically
dissociated. Cells were seeded at a density of 104 cells/
cm2 as described previously [8]. Cultures were main-
tained in a humidified incubator at 37°C, 5% O2 and 5%
CO2 and allowed to proliferate as free-floating clusters
(neurospheres).
Cell propagation and expansion
7–10 days after the primary cell seeding the neuro-
spheres that had formed were collected and mechanic-
ally dissociated and replated at the same initial density.
This step (passaging) was routinely repeated up to 17
times before the cells were supplied to the surgery site
on the day of transplantation. Throughout these pas-
sages aliquots of cells were frozen as neurospheres,
which were cryopreserved in 10% DMSO (Dimethyl sulf-
oxide, LiStarFish) culture medium as a pharmaceutical
intermediate product, with an assigned batch number.
This freezing step was conducted in order to coordinate
the timing of cell production with the surgery schedule.
It also allowed for the establishment of an “Intermediate
Product” to warrant the series of quality controls re-
quired to certify the safety, identity, potency and the
pharmaceutical grade of the donor hNSCs, to satisfy the
AIFA, GMP regulatory process criteria. Once the date of
the surgery had been determined, the intermediate prod-
uct was thawed and cells underwent additional passages
and expansion (a maximum of 17 times overall, as stated
above), until they were delivered to the surgery room as
the “final product” (cell drug) to be transplanted.
Cell quality control
In agreement with the AIFA certification criteria, we
subjected cells to serial quality control testing through-
out the whole production process (IPCs-In Process
Controls). Additional control tests were performed on
the Intermediate Product and Finished Product before
their final release.
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crobial monitoring of the product (Total Microbial
Count) and to evaluate cellular growth parameters (cell
counting and trypan blue exclusion method) throughout
all cell passages. Standard haematoxylin and eosin stain-
ing and histological evaluations were also carried out on
the fetal donor tissue to confirm the neural nature of the
starting material. This was in addition to the precise
anatomical dissection criteria used to isolate the initial
tissue. The release tests, performed at the very last
passage, were meant to verify the sterility of the product,
the absence of mycoplasma and a low level of endo-
toxin contamination (LAL test; < 1EU/ml) according to
European Pharmacopeia. A critical parameter such as
the “stemness” of the intermediated products and of the
cells in the cell drug suspension was routinely certified by
monitoring the most critical hNSCs parameters, such as
self-renewal activity, differentiation capacity and growth
factor dependence.
Self-renewal
In the culture system at hand, this could be extrapolated
by determining the cells growth kinetic. In fact, in the
neurosphere system, the slope of the growth curve pro-
vides an indirect index of the hNSCs’ inherent ability for
self-renewal [25,26]. We determined such kinetic curve
by calculating the estimated overall cell number increase
at each passage, as described earlier [8] and did confirmFigure 2 Cell quality control. (A) Growth kinetics of a set of hNSCs lines
(B) Clonal efficiency assay showing the percentage of cells that retain the a
reported (Replicates n = 3), bars describe standard error. (C) hNSCs differen
and oligodendrocytes (right, GalC, red); nuclei are counterstained in blu
extinction in vitro upon growth factor removal, as shown by the negati
in a few passages.the long-term stability of these cultures with respect to
this parameter (Figure 2A).
Clonal efficiency assay
The analysis of the clonogenic capacity throughout pas-
saging was used to directly confirm the stability of the
self-renewal capacity of our hNSCs. This was deter-
mined by the hNSCs clonal efficiency assay, which
shows the percentage of plated cells that retains the abil-
ity to form clonal neurospheres under stringent culture
conditions. Briefly, neurospheres were mechanically
dissociated and cells were counted, also assessing cell vi-
tality by trypan blue exclusion. Cells were seeded at a
density of 250 viable cells/cm2 on a Poly-L-lysine layer
(Sigma-Aldrich) in a flat bottom 24-well dish and incu-
bated at 5%O2 5%CO2 and 37°C in DMEM/F12, in the
presence of both mitogens, human recombinant EGF
and basic FGF. After 7 days of incubation, neurospheres
that measured between 50 μm and 100 μm in diameter
were counted under an inverted microscope. Clonal effi-
ciency was determined as the ratio between the total cell
seeded and the number of neurospheres obtained. An
example of this analysis and of stable clonogenic ability
in serially subcultured hNSCs is shown in Figure 2B.
Differentiation test
A critical feature of hNSC is their multipotency, i.e. their
ability to give rise to the three major neural lineages [8].showing the increasing, estimated overall cell number at each passage.
bility to form clonal neurospheres over the total cell number plated is
tiate into astrocytes (left, green, GFAP), neurons (left, red, βIII-tubulin)
e (DAPI). (Bar = 50 μm). (D) All of the hNSCs lines tested undergo
ve growth kinetic in which the total cell number approaches zero
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acity throughout culturing, their multipotency was
determined by in vitro differentiation tests, in which the
simultaneous presence of neurons, astrocytes and oligo-
dendrocytes was detected by immunocytochemical
labeling (β-tubulin III, neuron marker; GFAP, astroglial
marker; GalC, oligodendroglial marker). Neurospheres
were mechanically dissociated and the cells were resus-
pended in the same culture medium used during their
routine culturing but in the absence of EGF and in the
presence of the sole bFGF. Cells were seeded on a
cultrex layer (Cultrex® Basement Membrane Extract,
Trevigen) and incubated at 5% O2, 5% CO2 and 37°C for
3 days. Then culture media was replaced with DMEM/
F12 supplemented with 2% FBS, w/o growth factors [27].
Cells were incubated for an additional 7 days, after
which they were fixed with 4% paraformaldheyde and
immunostained using a standardized method [8]. An
example of such a differentiation test is shown in
Figure 2C.
Growth factor dependence
Neural stem cells appear to be quite resilient to trans-
formation. Both mouse and human cells depend on the
presence of mitogens to undergo proliferation and
promptly differentiate upon their removal from the cul-
ture [28]. Thus, ensuing growth factor independence is
considered as a sign of potential hNSCs transformation.
Hence, we routinely monitored growth factor depend-
ence in our GMP-grade hNSCs, in order to provide in-
direct evidence to their lack of transformation andFigure 3 The cell lines used in this study were confirmed to retain a n
example of a karyogram performed on the hNSC line from a female donor
routinely performed on both the Intermediate Product and the Finished Pr
were left in the needle, post-transplantation.tumorigenicity. This was evaluated by shifting expanding
cells to a culture media without EGF and bFGF and ana-
lyzing their growth curve upon further sub-culturing.
The latter ought to display a negative slope, confirming
the cells’ inability to sustain self-renewal in the absence
of mitogenic stimulation, as shown in Figure 2D.
Karyotype
We also monitored the stability of the hNSCs karyotype
all throughout passaging in culture. Chromosome G-
banding confirmed that the two cell lines used in this
study retained their normal, 46 XX or 46 XY karyotype
profile all throughout culturing (Figure 3). Forty eight to
120 hours from seeding, cell cultures (higher than
1,000,000 cells) were treated for three hours with colce-
mid solution (KaryoMAX® Colcemid® Solution, 10 μg/ml)
at a final concentration of 0.05 μg/ml to arrest cells in
metaphase. Cells were then treated with hypotonic so-
lution (0.075 M potassium chloride solution, SIGMA)
and with a fixative solution, prior to proceeding with
the karyotype analysis.
Tumorigenicity test in vivo
The lack of tumorigenicity in hNSCs was also evaluated
directly by in vivo safety testing. Immunodeficient,
athymic nude mice, were injected into the lateral striatum
(Figure 4A) with 3 × 105 hNSCs. They were sacrificed six
months later. Immunohistochemistry analysis showed that,
as seen previously [8], hNSCs engraft efficiently, with only a
few sporadic cells remaining positive for the human prolif-
eration antigen Ki67. Engrafted cells differentiated intoormal karyotype all throughout passaging. The figure shows the
(46, XX) after seventeen passages. Chromosome G-banding was
oduct. In addition we also tested for karyotype stability the cells that
Figure 4 hNSCs transplant into Nude Mice CNS. The lateral striatum of nude mice was the target area (A, arrow) for the transplantation of
normal hNSCs (B) or glioblastoma cancer stem cells (GBM; positive graft controls; C). Mice were sacrificed six (B) and two months (C) after
transplantation, respectively. The hematoxilyn/eosyn stain showed that structural organization of the transplanted regions was well preserved in
mice tranplanted with hNSCs (B), whereas hypercellularity and anomalous growth and necrosis ensued in regions receiving GBM cells (C).
Confocal microscopy of anti-human nuclei staining (huN, green, D) showed that hNSCs engrafted efficiently, with only a few human cells
retaining residual proliferation activity as shown by co-labeling with the proliferation marker ki67 (red). hNSCs labeled with huN (E, green)
differentiate into βTubIII+ neurons (E, red) and GFAP+ astrocytes (F, red). Nuclei are shown by DAPI staining. Scale bars: D-E = 15 μm; all insets:
10 μm, bar in inset D.
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astrocytes expressing the glial fibrillary acidic protein
(GFAP) (Figure 4D, E, F). We observed neither signs of
hyperproliferation (only an average of 4.83 ± 1.12% of Ki67
positive cells per transplant were found in the 20 animals
analyzed per each cell line (n = 15)) nor tumor formation
(Figure 4B). We also ran positive controls to verify that the
system used here was truly capable to detect the presence
of engrafted cells with tumorigenic ability (positive con-
trols). To this end, we set up a parallel group of trans-
planted nude mice that received between 50 and 50.000
transformed human neural cancer stem cells [29]. In these
animals, immunohistochemistry analysis promptly revealed
formation of hypercellular, invasive tumor cell masses
as early as 3 months after transplant at the highest
concentration and approximately 5 months for the
lowest (Figure 4C).
Surgical procedure
The details of the surgical apparatus and transplantation
protocol have been published previously [18]. Briefly, aplatform was fixed to the spine through percutaneous
posts. After laminectomy (T8-T11) and dural opening a
“floating retracting cannula” design was used to place a
needle precisely into the ventral horn, using a rigid con-
formation. After placement, the cannula was retracted
and converted to its flexible form to allow it to float
jointly liable with the spinal cord. Unlike the previous
trial we decided to use a cannula with a broader, 25
gauge diameter (instead of 30) to facilitate cells loading
and to minimize their reflux along the needle track
during infusion, also in consideration of the high cell
concentration of our cell suspension, which was 5 folds
higher than those previously used [30]. On average, the
time required for the entire surgery procedure was ap-
proximately 4 hours. Before implantation cells were
counted and suspended in HBSS buffer (Hank’s BSS 1X,
PAA) at a concentration of 50,000 cells/μl. After batch
release, cells were maintained at 2-8°C for not more than
1 hour prior to implantation. Patients received either
unilateral (Group A1) or bilateral (Group A2) NSCs mi-
croinjections (3 microinjections on each side) into the
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15 μl of the above 50,000cells/μl suspension, yielding a
total of 750,000 cells per injection site. Standard Moni-
toring techniques were applied during surgery and in-
cluded lower extremity somatosensory and motor
evoked potentials, when readings proved reliable. All
surgical procedures were performed under general an-
aesthesia using previously described procedures [31].
Cefazolin 1 g IV was administered at the time of dural
opening and immediately after surgery.
Immunosuppression
Methyprednisolone 125 mg IV was administered pre-
operatively at 2 hours before incision. Patients subse-
quently received oral prednisone, with a 28-day taper
and a dose change each week, declining from 60 mg to
40 mg, 20 mg, and 10 mg orally, every day.
Tacrolimus was administered orally at 0.1 mg/kg twice
a day, beginning on post-operative day 1. The drug was
titrated so as to maintain blood levels comprised be-
tween 5–10 ng/ml for 6 months, after which the treat-
ment was terminated.
Postoperative care and rehabilitation program
After surgery patients were admitted to the Intensive
Care Unit and mobilized. On postoperative day 3 pa-
tients were admitted in the neurosurgical unit and on
day 5 or 7 (depending on the patient conditions) were
transitioned to physical rehabilitation department for a
20-day period of intensive physical therapy. Neurological
status, including assessment of muscle strength by MRC
and spasticity by Ashworth scale and general examin-
ation (including blood pressure), biochemistry (renal
function, liver function, glucose, tacrolimus levels) and
haematological assessments (full blood and CD4 count)
were performed daily during the first week post-surgery.
This procedure was carried out weekly for the first three
weeks and monthly, thereafter. FVC was performed
monthly.
Discontinuation of the study
The study could be halted at any time either by the
Safety Monitoring Board, by the ISS, by the investigator
(s) or by the ethics committees, based on any medical
event experienced by the patient, which was deemed to
be of clinical significance and that might occur after the




We received a total of 227 applications to participate in
this study, 185 of which turned out to be ineligible since
they did not meet the inclusion criteria. A total of 18eligible patients were summoned for the initial medical
screening at the recruitment centres. After the visit and
detailed discussion of the informed consent 9 patients
withdrew their request to participate. Three of the pa-
tients that were enrolled developed respiratory failure
during the three months of observation of the disease
natural history prior to transplantation. This made it im-
possible for them to safely undergo surgery. The final
cohort of patients included 6 sporadic ALS patients (2
females and 4 males). The principal characteristics of the
recruited patients are described in Table 2.
Their median age was 46 years (Range: 30–67). The
median duration of the disease from the onset of symp-
toms to recruitment was 48 months (Range: 16–72).
The median ALS-FRS-R score at the study entry was 28
(Range: 24–35), while the median FVC was 82% (Range:
64–83).
Adverse events
The treatment caused no severe adverse events. All pa-
tients were extubated without problems in the operating
room and showed no immediate, post-operative respira-
tory difficulties. The most common adverse event was
post-surgical pain, as reported immediately after surgery.
This was confined to the injection sites and to the corre-
sponding dermatomes, with only one patient (number
753) experiencing transient, painful spasms in the lower
limbs. Pain was mild (WHO II-III) and well compen-
sated with narcotic and non-narcotic analgesics, disap-
pearing an average 4 days after surgery (Range: 1–6).
There was no correlation with the number of the injection
sites. One patient (number 779) developed deep vein
thrombosis in the leg 3 months after surgery, which re-
quired anticoagulant treatment. Subsequently a hematoma
at the site of surgical scar was observed. MRI confirmed
that the blood and oedema at this site were superficial and
confined to the epidermal layer. The hematoma showed
no clinical neurological correlate and readily resolved
upon drainage.
No patients suffered side effects from immunosup-
pressive treatment. Tacrolimus was well tolerated and
did not have to be suspended prematurely. All patients
showed tacrolimus blood levels that were within the
therapeutic target range, confirming compliance. Renal
and liver function, blood and CD3+; CD3+/CD8+ CD4+/8+
counts remained within normal range.
SEPs and MEPs showed no changes of the sensory and
motor conduction time during and following surgery.
Bladder ultrasound showed no abnormal post-void re-
sidual volumes.
MRI results
There were no post-procedural complications. In all
patients post-surgical MR scans revealed an expected
Table 2 Clinical characteristics of patients
Patient (Code) Group Age Sex ALS-FRS-R Score FVC Disease duration at entry Follow up duration
(%) (Months from symptoms onset) (Months from surgery to death
(†) or to the last visit)
740 A1 30 M 25 74 60 18
746 A1 57 M 28 64 68 8†
753 A1 54 F 29 83 16 8†
766 A2 35 M 30 82 72 12
767 A2 67 F 35 88 36 8†
779 A2 38 M 24 82 24 7
A1; unilateral hNSCs microinjections.
A2; bilateral hNSCs microinjections.
†; death.
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resolved spontaneously after 3 to 6 months (Figure 5A-G).
Serial MRI showed no structural changes (including
tumor or syrinx formation) within the brain and the
spinal cord after transplantation relative to the baseline
(Figure 5). A 12 months follow-up analysis in 2 out of 6
patients portrayed no significant, long lasting changes
in the Apparent Diffusion Coefficient (ADC) and Frac-
tional Anisotropy (FA). At post-surgery day 21 a slight
reduction of the FA values was observed, followed by a
subsequent recovery at later follow-up scans. ADC, which
probes the interstitial space restriction in the case of is-
chemia or cytotoxic oedema or, conversely, facilitationFigure 5 MRI Follow-up. T2 weighted sequences acquired on sagittal pla
(image D), 6 (image E), 9 (image F) and 12 months (image G) after transpla
collection at the site of surgery, which resolved spontaneously. No stru
to the baseline.of water diffusion in the case of increased extracellular
interstitial water, showed no evidence of post-transplant
damage. Neither brain morphological and signal altera-
tions nor pathological enhancements were detected 12
months after surgery.
Post-Transplantation hNSCs safety/identity tests
The few microliters of residual hNSCs suspension that
were left inside the injection cannula were harvested at
the end of the whole transplantation procedure and put
back into culture. By applying the same set of analysis
adopted for their initial GMP certification, we were able
to determine that the implanted hNSCs had retained thene before surgery (images A-B) and respectively 21 days (image C), 3
ntation. Post-surgical MR scans revealed an expected extradural fluid
ctural changes were detected after hNSCs transplantation relative
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renewal and multipotency and lack of tumorigenicity
upon in vivo implantation into immunodeficient mice
(Figure 6).
An aliquot of the very same cells that were injected
into the patients’s spinal cord were fixed the day of the
intervention and tested for karyotype stability, as de-
scribed into methods section. All of the cells used in this
study showed a normal chromosomal asset (see example
in Figure 3).
Follow-up
Clinical assessments ranging from 6 to 18 months after
transplantation showed no acceleration in the course of
progression of the disease due to the treatment. No sig-
nificant modifications in the decline of all clinical and
instrumental measures were observed between the pre-
and post-transplantation phases (Figure 7).
Patients 740 and 779 showed a transitory improve-
ment in the ambulation sub-score on the ALS-FRS-R
scale (from 1 to 2), which persisted 3 and 1 month after
surgery, respectively. Patient 753 showed an improve-
ment of the MRC score for tibialis anterior (from 1 to 2)
that persisted for up to 7 months after surgery.
Eight months after surgery, patient 753, together with
two additional patients (746 and 767), died due to the
progression of respiratory failure related to the natural
course of the disease. All the three of them had refused
PEG and invasive ventilation. The autopsies of patients
746 and 753 documented no other causes of death. TheFigure 6 Post Transplant hNSCs Test. (A) an example of human neural s
culture were they re-established typical neurosphere, expanding lines, with
the transplant, as shown in B. These cells differentiated into neurons (βIII-T
(GalC, Red, D). E: an example of whole brain reconstruction from one out o
with the cells recovered from the transplant and recultured, showing n
Bar in D.autopsy of patient 767 was not carried out because the
relatives declined the necessary consent. Histopatho-
logical, post-mortem analysis from the one patient from
whom the spinal cord tissue could be harvested showed
neither tissue abnormalities nor the presence of hyper-
cellular regions (Figure 8).Neuropsychological assessment
No negative reactions on the patients’ mood and quality
of life were observed. Only patient 753 experienced al-
terations in his mood, accompanied by depressive symp-
toms in the post-surgery period. This emerged as a
reaction to the paucity of assistance that she/he received,
from her/his family and the progressive deterioration of
the relationship with her/his spouse. The mood im-
proved after the activation of the domiciliary assistance
from the public health services. All patients were inter-
viewed at the last visit and confirmed that they were sat-
isfied by their participation in this study.
This study on six patients with ALS shows that trans-
plantation of hNSCs into the anterior horns of the lum-
bar spinal cord appears to be a safe procedure that
causes no major, short- or medium-term, deleterious ef-
fects. Our data are consistent with those reported previ-
ously [18,19,32]. Of importance, our findings emerge
from a similar experimental and clinical protocol that is
comparable to these studies but we, in turn, employed a
much higher cell dosage and a milder immunosuppres-
sion regimen.tem cells that were leftover from the transplant and put back in
a growth profile that mirrored that of the very same cultures prior to
ubulin, green, C) and astrocytes (GFAP, Red, C) and oligodendrocytes
f 10 nude mice that were transplanted into the right lateral striatum
o hyperplastic areas or tumor formation. Bars: A, 100 μm C,D 50 μm,
Figure 7 Clinical follow-up. Changes of the Forced Vital Capacity (upper panel) and of the ALS-FRS score (lower panel) in the 3-month period
of natural history observation and after transplantation. The arrow indicates the time of NSCs transplantation.
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Figure 8 Representative cross section of the spinal cord in the
region of transplantation stained with luxol fast blue and
periodic acid Schiff. There is no apparent disruption of tissue due
to injection. Note the degeneration of the cortico-spinal tracts
(“lateral sclerosis”). The inset demonstrates a phosphorylated TDP43
inclusion in a remaining motor neuron. Scale bars are 1 mm for the
low power and 20 microns for the inset.
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gery underpinning intraspinal cell injection in humans
appears to be a safe, reproducible and reliable procedure.
Also, perspective improvements were made here, par-
ticularly concerning the number of implanted cells, that
in our study was four and a half times higher than in
previous approaches – a maximun of 4.5 × 106 cells/pa-
tient used here versus the previous 1 × 106 cells [32]. In
addition, we adopted a floating cannula with a larger
diameter. This further reduced the risk of the cells clog-
ging the needle, and minimized their flowing back along
the walls of the needle track through the cell infusion
procedure, irrespective of their higher concentration in
our cell suspension.
Second, MRI scans revealed no structural changes or
tumor formation in the spinal cord parenchyma all
throughout the follow-up period. The analysis of Appar-
ent Diffusion Coefficient (ADC) and Fractional Anisot-
ropy (FA) did not show any damage to the spinal tissue.
Of note, FA is a parameter that probes the axonal dens-
ity. Thus a lesion of the spinal cord should induce a
definite and long lasting reduction of FA. In our
18 month-long follow up we observed no significant,
long-lasting changes in the FA values. This was further
confirmed by the histopathological, post-mortem analysis.
At present, any interpretation of the slight clinical im-
provement observed in three patients remains highly
speculative. Notwithstanding, by taking the evidence
available from the literature into account, some cautious
hypothesis can still be put forth, if only tentatively. Such
effects could be related to the well known ability of
NSCs to ameliorate the pathophysiological and neuro-
logical traits in many animal models of neurologicaldisorders, including ALS [13]. This may occur through
the release of neurotrophic and growth factors, cytokines
and immunomodulatory molecules [33] that diffuse into
the pathological tissue, thereby eliciting multifaceted,
anti-inflammatory and anti-gliosis effects. In agreement
with this view, we have recently found that the same cell
used in this trial can effectively reduce reactive microglia
in the spinal cord of SOD1G93A rats (Vescovi et al.,
manuscript in preparation). Intriguingly, compelling
evidences now exist that implanted NSCs, which inte-
grate and survive predominantly as astroglial cells in
the brain parenchyma, exert their immunomodulation
ability through secretion of extracellular membrane
vesicles (EMVs), influencing the microenvironment
through the traffic of bioactive molecules [34,35]. If
the above were the case, it would also help to explain
as to why these mild clinical improvements may occur
irrespective of the total number of injections, as ob-
served here.
An additional, significant finding from this study is the
lack of acute or delayed toxicity that might have ensued
from the transplantation of our hNSCs lines. The latter
are routinely generated anew and banked as tissue be-
comes continuously available over time. This approach
has now allowed us to establish a GMP-certified, clinical
grade bank of hNSCs, which is constantly expanding
both in size and donors repertoire. Each single hNSCs line
is steadily and plentifully expandable ex vivo, with multi-
potentiality and functional characteristics remaining stable
and certified throughout time. Thus, not only does this ap-
proach provide a broad array of different hNSCs lines for
future studies – allowing for determining if cells from dif-
ferent regions or developmental ages may be more amen-
able for cell therapy in different pathological contexts –
but also enables us to carry out this whole phase I trial
using cells from a maximum of two donors.
Previous pre-clinical data from our lab using these
same hNSCs pointed to a low expression profile of HLA
molecules. Furthermore, negligible immunological reac-
tion was observed following intracerebral transplantation,
upon transient (peri-transplantation) immunosuppression
[10]. Hence, in considering that ALS patients at advanced
stages of the disease might be weaker and more vulnerable
to pharmacological toxicity, in the study reported here we
adopted a reduced immunosuppression regimen as com-
pared to that employed by Glass and colleagues [19]. As
expected, we observed a smaller cohort of side effects aris-
ing from the immunosuppressive treatment.
While transplantation of cells from human foetuses is
an accepted technique, it is undeniable that such an ap-
proach is often met with ethical and moral concern, par-
ticularly outside the scientific community. At times,
heated public debates have escalated to worrisome levels
due to the fact that, to date, this tissue has always been
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also explains as to why approval from ethical commit-
tees may encounter significant hurdles when the use of
foetal material is involved. To the best of our knowledge,
this is the first time that a procedure for the isolation of
hNSCs is successfully carried out from foetuses that
were certifiably deceased in utero due to natural causes.
Also, tissue procurement in this study took place ac-
cording to the same international guidelines that are in
place for the donation of organs for therapeutic trans-
plantation. Hence, this provides an approach to hNSCs
transplantation that is free from the ethical concerns
that may arise from the use of foetal human tissues.
In all experimental and clinical transplantation studies
on hNSCs, the lack of univocal hNSC markers makes it
difficult to precisely define the actual composition of the
transplanted cell suspension. This matter is further com-
pounded by the fact that implanted cells undergo signifi-
cant stress due to their preparation for transplantation,
their transportation and loading into the needle and
throughout the injection process. Up until now, it could
not be ruled out that the cells death that inevitably oc-
curs throughout these procedures might significantly or
even prevalently affect the hNSCs pool in the injected
cell suspension. As paradoxical as it may seem, the
chances still exist that the stem cell content in the cell
suspension that eventually reaches the patient’s own tis-
sue in hNSCs transplantation procedures may drop sig-
nificantly, even to the point that the final graft might
actually contain negligible amounts of bona fide brain
stem cells. Here we were able to recover the few cells
that were left in the injection needle following trans-
plantation and to examine them thoroughly. By this, we
were able to show that the cells that were injected into
the ventral horns of the spinal cord of ALS patients
were, in fact, the same hNSCs suspension that were
released from the cell factory that, as such, did retain
key features of stemness and lack of tumorigenicity
(Figure 6).
We are now routinely carrying this procedure out.
This introduces an additional level of control on the
cell composition and quality that should help improve
standardization of hNSC-based cell therapies in future
trials.
We have been able to reproducibly and quite exten-
sively expand hNSCs ex-vivo. Thus, this whole trial is ac-
tually based on the use of only two donors. The use of
such a limited number of donors inherently reduces the
inter-treatment variability that may arise from the im-
plantation of different hNSC lines into different patients.
Very few studies in the scientific literature report the
results of clinical trials with stem cell transplantation.
These results are not definitive and no trial has been
replicated in multiple centres. Experimental neuraltransplantation inevitably involves only relatively small
groups of patients, with a corresponding loss of statis-
tical prowess. Hence, only international collaboration
may accomplish the most effective progress in stem
cell clinical trial. This is the first report of an inter-
national coordinated effort about the cell therapy and
transplantation approach in ALS patients. By utilizing
a methodology similar to that adopted by our collabo-
rators [18], we have reproduced the safety of the ap-
proach and provided an improved ability to compare
the relative efficacy of the different cell types, also fac-
toring out variance in the approach to delivery. A
large multidisciplinary team of cell biologists, neurolo-
gists and neurosurgeons with significant experience in
experimental cell therapy and in the treatment of ALS
are involved in our studies. These researchers worked
closely with regulatory agencies (AIFA, ISS), patient
advocacy groups and ethical regulatory bodies. More-
over this is the first clinical trial with hNSCs that is
run entirely by a not-for-profit organization, strictly
on a charitable fund raising basis.
We are now broadening the import of this trial by
testing intraspinal injections into the cervical spinal cord
(C3-C4 level) of 12 ambulatory patients.
Conclusions
We can conclude that, while these results are not defini-
tive, it appears that transplantation of human fetal
neural cells in the lumbar spinal cord is a safe proced-
ure. This technique has now been freed of any ethical
concerns arising from the use of human fetal tissue. In
addition, up to five fold more cells can now be safely im-
planted into the human spinal cord and a milder im-
munosuppression regimen adopted in ALS patients in
the absence of related adverse effects.
We will next compare our results with the findings
from the recently concluded trial at Emory University,
which will help both groups to extend and deepen their
conclusion on the use of cell therapy in ALS.
The results from this investigation also describe a cell
therapy platform that will allow broadening the number
and reproducibility of cell therapy clinical trials for ALS
and, other neurological disorders. These can now be car-
ried out under more standardized conditions and will be
based on a more homogenous repertoire of clinical
grade, donor hNSCs, which also avoid ethical concerns.
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